{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:13:37Z","timestamp":1792602817392,"version":"4.5.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inflammatory monocytes have been shown to play key roles in cancer metastasis through promotion of tumor cell extravasation, growth, and angiogenesis. Monocyte recruitment to metastases is mediated primarily via the CCL2\u2013CCR2 chemotactic axis. Thus, disruption of this axis represents an attractive therapeutic target for the treatment of metastatic disease. Losartan, a type I angiotensin II receptor (AT1R) antagonist, has been previously shown to have immunomodulatory actions involving monocyte and macrophage activity. However, the exact mechanisms accounting for these effects have not been fully elucidated. Therefore, we investigated the effects of losartan and its primary metabolite on CCL2-mediated monocyte recruitment and CCR2 receptor function using mouse tumor models and in vitro human monocyte cultures. We show, in this study, that losartan and its metabolite potently inhibit monocyte recruitment through the noncompetitive inhibition of CCL2-induced ERK1\/2 activation, independent of AT1R activity. Studies in experimental metastasis models demonstrated that losartan treatment significantly reduced the metastatic burden in mice, an effect associated with a significant decrease in CD11b+\/Ly6C+-recruited monocytes in the lungs. Collectively, these results indicate that losartan can exert antimetastatic activity by inhibiting CCR2 signaling and suppressing monocyte recruitment and therefore suggest that losartan (and potentially other AT1R blocker drugs) could be repurposed for use in cancer immunotherapy.<\/jats:p>","DOI":"10.4049\/jimmunol.1800619","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T20:15:10Z","timestamp":1554927310000},"page":"3087-3102","source":"Crossref","is-referenced-by-count":69,"title":["The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment"],"prefix":"10.1093","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3148-1332","authenticated-orcid":false,"given":"Daniel P","family":"Regan","sequence":"first","affiliation":[{"name":"Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"},{"name":"Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W","family":"Coy","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"},{"name":"Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-4161","authenticated-orcid":false,"given":"Kirti Kandhwal","family":"Chahal","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego , La Jolla, CA 92093"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndah","family":"Chow","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"},{"name":"Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade N","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"},{"name":"Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-6528","authenticated-orcid":false,"given":"Amanda M","family":"Guth","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"},{"name":"Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-7039","authenticated-orcid":false,"given":"Irina","family":"Kufareva","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego , La Jolla, CA 92093"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-9464","authenticated-orcid":false,"given":"Steven W","family":"Dow","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"},{"name":"Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO 80523"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"2025030417562171900_r1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nrc1886","article-title":"Metastasis: a question of life or death","volume":"6","author":"Mehlen","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"2025030417562171900_r2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ejca.2010.02.030","article-title":"Cancer stemness and metastasis: therapeutic consequences and perspectives","volume":"46","author":"Monteiro","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"2025030417562171900_r3","author":"Howlader","year":"2016"},{"key":"2025030417562171900_r4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrc1670","article-title":"Breast cancer metastasis: markers and models","volume":"5","author":"Weigelt","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"2025030417562171900_r5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","article-title":"Extending survival with chemotherapy in metastatic breast cancer","volume":"10","author":"O\u2019Shaughnessy","year":"2005","journal-title":"Oncologist"},{"key":"2025030417562171900_r6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/annonc\/mdp130","article-title":"Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann. Oncol."},{"key":"2025030417562171900_r7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc.2016.25","article-title":"Targeting metastasis","volume":"16","author":"Steeg","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"2025030417562171900_r8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2025030417562171900_r9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"2025030417562171900_r10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"2025030417562171900_r11","doi-asserted-by":"crossref","first-page":"10667","DOI":"10.1074\/jbc.M114.612622","article-title":"Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-mediated inflammatory cell infiltration","volume":"290","author":"Piao","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2025030417562171900_r12","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1084\/jem.20141555","article-title":"FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis","volume":"212","author":"Qian","year":"2015","journal-title":"J. Exp. Med."},{"key":"2025030417562171900_r13","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ccr.2011.08.025","article-title":"Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs","volume":"20","author":"Chen","year":"2011","journal-title":"Cancer Cell"},{"key":"2025030417562171900_r14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ccr.2011.02.005","article-title":"Targeting the ANG2\/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells","volume":"19","author":"Mazzieri","year":"2011","journal-title":"Cancer Cell"},{"key":"2025030417562171900_r15","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-13-0525","article-title":"Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis","volume":"19","author":"Sanford","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2025030417562171900_r16","first-page":"596","article-title":"Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection","volume-title":"J. Gastrointest. Surg.","author":"Sasaki","year":"2007"},{"key":"2025030417562171900_r17","doi-asserted-by":"crossref","first-page":"e111886","DOI":"10.1371\/journal.pone.0111886","article-title":"An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy","volume":"9","author":"Ni","year":"2014","journal-title":"PLoS One"},{"key":"2025030417562171900_r18","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-15-0204","article-title":"CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer","volume":"21","author":"Svensson","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"2025030417562171900_r19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00280-013-2099-8","article-title":"A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors","volume":"71","author":"Sandhu","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2025030417562171900_r20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol."},{"key":"2025030417562171900_r21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.2006.09.0803","article-title":"Economics of new oncology drug development","volume":"25","author":"DiMasi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"2025030417562171900_r22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025030417562171900_r23","first-page":"877","article-title":"New drugs cost US$2.6 billion to develop","volume":"13","author":"Mullard","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025030417562171900_r24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology--patient and health systems opportunities","volume":"12","author":"Bertolini","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2025030417562171900_r25","doi-asserted-by":"crossref","first-page":"14942","DOI":"10.1073\/pnas.0903602106","article-title":"Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system","volume":"106","author":"Stegbauer","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417562171900_r26","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.atherosclerosis.2015.02.055","article-title":"Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice","volume":"240","author":"Yang","year":"2015","journal-title":"Atherosclerosis"},{"key":"2025030417562171900_r27","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/sj.bjp.0707454","article-title":"Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats","volume":"152","author":"Dai","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"2025030417562171900_r28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4682-3-1","article-title":"Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b","volume":"3","author":"Marshall","year":"2006","journal-title":"Theor. Biol. Med. Model."},{"key":"2025030417562171900_r29","doi-asserted-by":"crossref","first-page":"e31384","DOI":"10.1371\/journal.pone.0031384","article-title":"Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGF\u03b2 activation","volume":"7","author":"Arnold","year":"2012","journal-title":"PLoS One"},{"key":"2025030417562171900_r30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00280-009-1136-0","article-title":"Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma","volume":"66","author":"Otake","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2025030417562171900_r31","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1172\/JCI119798","article-title":"Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice","volume":"100","author":"Boring","year":"1997","journal-title":"J. Clin. Invest."},{"key":"2025030417562171900_r32","doi-asserted-by":"crossref","first-page":"46144","DOI":"10.1038\/srep46144","article-title":"NOX4 regulates CCR2 and CCL2 mRNA stability in alcoholic liver disease","volume":"7","author":"Sasaki","year":"2017","journal-title":"Sci. Rep."},{"key":"2025030417562171900_r33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2199-11-90","article-title":"Selection of reliable reference genes during THP-1 monocyte differentiation into macrophages","volume":"11","author":"Maess","year":"2010","journal-title":"BMC Mol. Biol."},{"key":"2025030417562171900_r34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/acschembio.5b00753","article-title":"NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells","volume":"11","author":"Dixon","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"2025030417562171900_r35","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1021\/acs.bioconjchem.6b00112","article-title":"NanoLuc: a small luciferase is brightening up the field of bioluminescence","volume":"27","author":"England","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"2025030417562171900_r36","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1038\/s41467-018-07094-0","article-title":"Crystal structures of human ETB receptor provide mechanistic insight into receptor activation and partial activation","volume":"9","author":"Shihoya","year":"2018","journal-title":"Nat. Commun."},{"key":"2025030417562171900_r37","doi-asserted-by":"crossref","first-page":"30760","DOI":"10.1074\/jbc.M204528200","article-title":"Differential roles of arrestin-2 interaction with clathrin and adaptor protein 2 in G protein-coupled receptor trafficking","volume":"277","author":"Kim","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2025030417562171900_r38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/eji.200324166","article-title":"Differential chemokine activation of CC chemokine receptor 1-regulated pathways: ligand selective activation of Galpha 14-coupled pathways","volume":"34","author":"Tian","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"2025030417562171900_r39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2125.1993.tb05696.x","article-title":"Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans","volume":"35","author":"Ohtawa","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2025030417562171900_r40","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.4049\/jimmunol.1202151","article-title":"Suppression of vaccine immunity by inflammatory monocytes","volume":"189","author":"Mitchell","year":"2012","journal-title":"J. Immunol."},{"key":"2025030417562171900_r41","doi-asserted-by":"crossref","first-page":"e0158156","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"2025030417562171900_r42","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1021\/jm1012903","article-title":"Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function","volume":"54","author":"Laborde","year":"2011","journal-title":"J. Med. Chem."},{"key":"2025030417562171900_r43","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.4049\/jimmunol.0802812","article-title":"Monocyte chemoattractant protein-1 (MCP-1), not MCP-3, is the primary chemokine required for monocyte recruitment in mouse peritonitis induced with thioglycollate or zymosan A","volume":"183","author":"Takahashi","year":"2009","journal-title":"J. Immunol."},{"key":"2025030417562171900_r44","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1172\/JCI29919","article-title":"Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites","volume":"117","author":"Tsou","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2025030417562171900_r45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1021\/ml200030q","article-title":"Discovery of INCB3284, a potent, selective, and orally bioavailable hCCR2 antagonist","volume":"2","author":"Xue","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"2025030417562171900_r46","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nature20605","article-title":"Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists","volume":"540","author":"Zheng","year":"2016","journal-title":"Nature"},{"key":"2025030417562171900_r47","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1124\/mol.64.3.773","article-title":"Signaling pathways for monocyte chemoattractant protein 1-mediated extracellular signal-regulated kinase activation","volume":"64","author":"Jim\u00e9nez-Sainz","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"2025030417562171900_r48","doi-asserted-by":"crossref","first-page":"16555","DOI":"10.1074\/jbc.M009068200","article-title":"Distinct signaling pathways for MCP-1-dependent integrin activation and chemotaxis","volume":"276","author":"Ashida","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2025030417562171900_r49","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.4049\/jimmunol.156.4.1356","article-title":"Early signal transduction by the receptor to the chemokine monocyte chemotactic protein-1 in a murine T cell hybrid","volume":"156","author":"Dubois","year":"1996","journal-title":"J. Immunol."},{"key":"2025030417562171900_r50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/jlb.61.4.529","article-title":"MCP-1-mediated chemotaxis requires activation of non-overlapping signal transduction pathways","volume":"61","author":"Yen","year":"1997","journal-title":"J. Leukoc. Biol."},{"key":"2025030417562171900_r51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2014.02.007","article-title":"Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists","volume":"729","author":"Ajram","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"2025030417562171900_r52","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/mol.110.068486","article-title":"Different effects of the different natural CC chemokine receptor 2b ligands on beta-arrestin recruitment, G\u03b1i signaling, and receptor internalization","volume":"79","author":"Berchiche","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"2025030417562171900_r53","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.4049\/jimmunol.166.7.4697","article-title":"Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice","volume":"166","author":"Mack","year":"2001","journal-title":"J. Immunol."},{"key":"2025030417562171900_r54","first-page":"2189","article-title":"Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells","volume-title":"J. Gastrointest. Surg.","author":"Chehl","year":"2009"},{"key":"2025030417562171900_r55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/carcin\/bgh324","article-title":"Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth","volume":"26","author":"Fujita","year":"2005","journal-title":"Carcinogenesis"},{"key":"2025030417562171900_r56","doi-asserted-by":"crossref","first-page":"10562","DOI":"10.4238\/2014.December.12.19","article-title":"Hypoxia induces dysregulation of local renin-angiotensin system in mouse Lewis lung carcinoma cells","volume":"13","author":"Fan","year":"2014","journal-title":"Genet. Mol. Res."},{"key":"2025030417562171900_r57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1515\/dmpt-2016-0006","article-title":"Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?","volume":"31","author":"Falvella","year":"2016","journal-title":"Drug Metab. Pers. Ther."},{"key":"2025030417562171900_r58","first-page":"355","article-title":"Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities","volume":"22","author":"Noguchi","year":"2009","journal-title":"Oncol. Rep."},{"key":"2025030417562171900_r59","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1357-2725(02)00271-6","article-title":"Inflammation and angiotensin II","volume":"35","author":"Suzuki","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2025030417562171900_r60","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/hep.26094","article-title":"Recruitment of a myeloid cell subset (CD11b\/Gr1 mid) via CCL2\/CCR2 promotes the development of colorectal cancer liver metastasis","volume":"57","author":"Zhao","year":"2013","journal-title":"Hepatology"},{"key":"2025030417562171900_r61","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.4049\/jimmunol.1202857","article-title":"Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2","volume":"190","author":"van Deventer","year":"2013","journal-title":"J. Immunol."},{"key":"2025030417562171900_r62","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/0008-5472.CAN-13-0946","article-title":"Metastatic growth progression caused by PSGL-1-mediated recruitment of monocytes to metastatic sites","volume":"74","author":"Hoos","year":"2014","journal-title":"Cancer Res."},{"key":"2025030417562171900_r63","doi-asserted-by":"crossref","first-page":"8389","DOI":"10.18632\/oncotarget.6690","article-title":"Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer","volume":"7","author":"Izumi","year":"2016","journal-title":"Oncotarget"},{"key":"2025030417562171900_r64","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/mol.114.093328","article-title":"Discovery and mapping of an intracellular antagonist binding site at the chemokine receptor CCR2","volume":"86","author":"Zweemer","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"2025030417562171900_r65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cyto.2013.12.008","article-title":"CXC chemokine receptor 4 signaling upon co-activation with stromal cell-derived factor-1\u03b1 and ubiquitin","volume":"65","author":"Tripathi","year":"2014","journal-title":"Cytokine"},{"key":"2025030417562171900_r66","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.cellsig.2006.05.001","article-title":"CrkL plays a role in SDF-1-induced activation of the Raf-1\/MEK\/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells","volume":"18","author":"Arai","year":"2006","journal-title":"Cell. Signal."},{"key":"2025030417562171900_r67","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/07357907.2011.616252","article-title":"Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and\/or statins","volume":"29","author":"Chae","year":"2011","journal-title":"Cancer Invest."},{"key":"2025030417562171900_r68","doi-asserted-by":"crossref","first-page":"21359","DOI":"10.1038\/srep21359","article-title":"Impact of angiotensin I-converting enzyme inhibitors and angiotensin II type-1 receptor blockers on survival of patients with NSCLC","volume":"6","author":"Miao","year":"2016","journal-title":"Sci. Rep."},{"key":"2025030417562171900_r69","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","article-title":"Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine","volume":"103","author":"Nakai","year":"2010","journal-title":"Br. J. Cancer"},{"key":"2025030417562171900_r70","doi-asserted-by":"crossref","first-page":"10284","DOI":"10.1073\/pnas.0900351106","article-title":"AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist","volume":"106","author":"Rhodes","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417562171900_r71","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/0008-5472.CAN-13-2825","article-title":"Monocyte subpopulations in angiogenesis","volume":"74","author":"Dalton","year":"2014","journal-title":"Cancer Res."},{"key":"2025030417562171900_r72","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"2025030417562171900_r73","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic-root dilation in Marfan\u2019s syndrome","volume":"358","author":"Brooke","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2025030417562171900_r74","first-page":"S23","article-title":"Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects","volume-title":"J. Hypertens. Suppl.","author":"Burnier","year":"1995"},{"key":"2025030417562171900_r75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0163-7258(97)82002-5","article-title":"Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension","volume":"74","author":"McIntyre","year":"1997","journal-title":"Pharmacol. Ther."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/202\/10\/3087\/61871761\/ji1800619.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/202\/10\/3087\/61871761\/ji1800619.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T20:08:24Z","timestamp":1741118904000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/202\/10\/3087\/7952198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1800619","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,5]]}}}